Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by New Hanover Regional Medical Center.
Recruitment status was  Recruiting
Coastal Carolina Radiation Oncology (CCRO)
Information provided by:
New Hanover Regional Medical Center Identifier:
First received: June 6, 2011
Last updated: June 10, 2011
Last verified: June 2011

Concurrent chemotherapy and radiation therapy (chemoRT) has become the standard of care for treatment of many patients with advanced head and neck squamous cell carcinoma (HNSCC), though many clinical questions remain. Prior experience has revealed locoregional control (LRC), disease free survival (DFS) and overall survival (OS) at 3 years exceeding 80% after treatment with the use of hyperfractionated intensity modulated radiation therapy (IMRT) and concurrent weekly cisplatin chemotherapy for patients with locally advanced HNSCC. This multi-institutional phase II ZCC00204 trial resulted in an acceptable quality of life (QOL) and toxicity profile. The current trial is an attempt to maintain high LRC, while further minimizing both acute and chronic toxicities, and maximizing QOL.

Condition Intervention Phase
Head and Neck Cancer
Drug: Cisplatin
Radiation: Elective Nodal Irradiation (ENI)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial

Resource links provided by NLM:

Further study details as provided by New Hanover Regional Medical Center:

Primary Outcome Measures:
  • To assess the actuarial elective nodal failure (ENF) rate for patients with locally advanced HNSCC treated with chemoRT including very low dose elective nodal IMRT and concurrent weekly cisplatin. [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess actuarial LRC, DFS, and OS rates. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • To evaluate patients' quality of life (QOL). [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • To evaluate grade 3-5 toxicity by CTCAE v4.0, with special attention to swallowing function, feeding tube dependence, and xerostomia. [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 76
Study Start Date: March 2011
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cisplatin
    Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
    Other Name: Cis-Diamminedichloroplatinum, DDP
    Radiation: Elective Nodal Irradiation (ENI)
    Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy proven squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, or larynx
  • No surgical resection of primary site or neck dissection (excisional biopsy of lymph node is permitted)
  • Human Papilloma Virus (HPV) testing of tumor performed; HPV p16 by immunohistochemistry
  • Stage III or IVa disease (T1-2N1-3M0, T3-4N0-3M0) excluding T1-2N1 oral cavity and tonsil primaries and any N2C or bilateral N3 disease. Patients with T2N0 cancer of the base of tongue and hypopharynx are eligible
  • ECOG performance status 0-1
  • Age >18 years
  • No current pregnancy
  • No other invasive malignancies within the last 2 years Patients with basal cell or squamous cell skin cancers or carcinoma in situ of any site are eligible.
  • No prior radiotherapy to the head and neck region
  • No prior cisplatin chemotherapy
  • No symptomatic coronary disease or myocardial infarction within the last 6 months
  • Laboratory evaluation: ANC > 2,000/mm3, platelets >100,000/mm3, creatinine < 1.5 mg/dl, creatinine clearance > 50 ml/min, bilirubin < 1.5 mg/dl, AST or ALT < 2X upper normal limit
  • Study-specific consent signed prior to entry

Exclusion Criteria:

  • Second primary malignancy that is clinically detectable
  • Inability or unwillingness to comply with chemoRT
  • Prior radiotherapy, chemotherapy, or investigational treatment for squamous cell carcinoma of head and neck.
  • Metastatic disease (M1)
  • Pregnant or breast-feeding women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01372111

Contact: Deborah Brasic, FNP 910-251-1839
Contact: Lynette Racco, RN, BSN, OCN 910-343-4075

United States, North Carolina
Coleman Radiation Oncology Center Recruiting
Morehead City, North Carolina, United States, 28557
CarolinaEast Cancer Care Recruiting
New Bern, North Carolina, United States, 28561
South Atlantic Radiation Oncology Recruiting
Supply, North Carolina, United States, 28462
Coastal Carolina Radiation Oncology Recruiting
Wilmington, North Carolina, United States, 28401
Zimmer Cancer Center Recruiting
Wilmington, North Carolina, United States, 28401
Sponsors and Collaborators
New Hanover Regional Medical Center
Coastal Carolina Radiation Oncology (CCRO)
Principal Investigator: Patrick D. Maguire, M.D. Coastal Carolina Radiation Oncology
  More Information

Responsible Party: Patrick D. Maguire, M.D., CCRO Identifier: NCT01372111     History of Changes
Other Study ID Numbers: CCRO11, U54CA142152-02
Study First Received: June 6, 2011
Last Updated: June 10, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by New Hanover Regional Medical Center:
Stg III or IVa Squamous Cell Carcinoma.

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Antineoplastic Agents
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on October 21, 2014